SEP 30, 2019 8:41 AM PDT

New Potential Early Stage Treatment for Parkinson's

WRITTEN BY: Annie Lennon

Parkinson’s Disease is the second most common neurodegenerative condition, affecting 35 million people globally. Currently without a cure, researchers from Stanford University have identified a molecular defect common to all people with the condition that may help pave the way for early diagnosis and new treatment options. 

In a study published in Cell Metabolism, researchers collected skin samples from 83 people with Parkinson’s, five asymptomatic close relatives thought to be at high risk of developing the condition, 22 people with other movement disorders and 52 healthy control subjects. Extracting the fibroblasts from the skin samples, they then cultured them in petri dishes and put them under stress to damage their mitochondria. Under normal circumstances, this process leads to the removal of Miro, an adaptor molecule, from damaged mitochondria, so they may then be repaired by the body (Hsieh: 2019). 

Although Miro was successfully removed from damaged mitochondria in the control group and those with other movement disorders, for those with Parkinson’s and their high risk relatives, the Miro remained. A clear indicator of how the early stages of Parkinson’s begin- by disabling the body from repairing damaged mitochondria, the researchers recognised that simple tests like this may help with early diagnosis of Parkinsons. Yet, they didn’t stop with this conclusion (ibid.). 

Screening 6,835,320 molecules, they used software from Atomwise to identify 11 molecules possibly capable of binding to Miro to facilitate its separation from mitochondria, that were nontoxic, orally available and able to cross the blood-brain barrier. Testing these compounds on fruit flies for seven days, the researchers found that four of them significantly reduced their Miro levels without negative side effects. Furthermore, the researchers also tested one compound on fibroblasts from a patient with sporadic Parkinson’s disease, noting substantial improvements on Miro clearance in their cells after their mitochondria was damaged. 

Although further research is needed to confirm the results, Xinnan Wang, the study’s senior author, “Our hope is that if this compound or a similar one proves nontoxic and efficacious and we can give it, like a statin drug, to people who’ve tested positive for the Miro-removal defect but don’t yet have Parkinson’s symptoms, they’ll never get it. (Stanford Medicine: 2019)”

 

Sources

 

Hsieh, Chung-Han et al: Cell Metabolism

Stanford Medicine 

 

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
DEC 09, 2019
Drug Discovery & Development
DEC 09, 2019
MagLev: Telling Drugs Apart
Likely, a suspicious powder will be composed of illicit drugs but nothing is certain until confirmation. To do so, analysis must be quick and efficient and...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
IV Treatment for Traumatic Brain Injury
Scientists are now using exosomes intravenously as a method of cell-to-cell technology for treating patients with traumatic brain injury (TBI). They discov...
DEC 22, 2019
Drug Discovery & Development
DEC 22, 2019
Effective Therapeutic Approved for Migraines
The U.S Food and Drug Administration has now approved a new medication for migraines. The drug is called ‘ubrogepant (Ubrelvy)’ and comes in th...
DEC 25, 2019
Drug Discovery & Development
DEC 25, 2019
New Drug to Make Breast Cancer Treatment More Affordable
The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recogni...
DEC 27, 2019
Drug Discovery & Development
DEC 27, 2019
New Drug to Treat Migraines Approved by FDA
Over 1 in 10 people around the world- or 780 million people. Three times more common in women than in men, until now, most treatments have been preventativ...
Loading Comments...